{"id":629,"date":"2023-02-22T16:05:19","date_gmt":"2023-02-22T15:05:19","guid":{"rendered":"http:\/\/localhost:8888\/progetti\/laramed\/?page_id=629"},"modified":"2025-07-17T11:05:54","modified_gmt":"2025-07-17T09:05:54","slug":"cuprum-ttd","status":"publish","type":"page","link":"https:\/\/web.infn.it\/LARAMED\/cuprum-ttd\/","title":{"rendered":"Cuprum-TTD"},"content":{"rendered":"<style>.wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9, .wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9[data-kb-block=\"kb-adv-heading629_00d9cd-d9\"]{text-align:center;font-size:var(--global-kb-font-size-md, 1.25rem);font-style:normal;}.wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9 mark.kt-highlight, .wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9[data-kb-block=\"kb-adv-heading629_00d9cd-d9\"] mark.kt-highlight{font-style:normal;color:#f76a0c;-webkit-box-decoration-break:clone;box-decoration-break:clone;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;}.wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9 img.kb-inline-image, .wp-block-kadence-advancedheading.kt-adv-heading629_00d9cd-d9[data-kb-block=\"kb-adv-heading629_00d9cd-d9\"] img.kb-inline-image{width:150px;vertical-align:baseline;}<\/style>\n<h2 class=\"kt-adv-heading629_00d9cd-d9 wp-block-kadence-advancedheading\" data-kb-block=\"kb-adv-heading629_00d9cd-d9\"><strong>CUPRUM_TTD (INFN-CSN5, 2023-2025)<\/strong><\/h2>\n\n\n\n<p class=\"has-theme-palette-3-color has-text-color has-link-color wp-elements-f7c2e8c6617eab4353b6ece4e39969cf\">CUPRUM_TTD project, acronym for &#8220;<strong><sup>67\/64<\/sup>Cu<\/strong> PRoduction and Use in Medicine and <em>Target Technology Development&#8221;<\/em> is dedicated to the production of copper radionuclides <strong><sup>67\/64<\/sup>Cu<\/strong>, currently considered among the best-suited isotopes for radioimmunotherapy and theranostic applications, used as single isotopes, or in pair. Currently, the large-scale production of <strong><sup>67<\/sup>Cu<\/strong> still remains challenging: only a few sites are producing it worldwide, while a stable supplier in Europe is still lacking. The production of <strong><sup>67<\/sup>Cu<\/strong> has been a top priority since the very early days of LARAMED project, as underlined by the <a href=\"https:\/\/web.infn.it\/LARAMED\/come\/\" data-type=\"page\" data-id=\"631\">COME<\/a> experiment.<\/p>\n\n\n\n<p class=\"has-theme-palette-3-color has-text-color has-link-color wp-elements-12eace81dd3b0c0b1238c5787755948d\">The goal of CUPRUM_TTD is, therefore, the R&amp;D of the technology necessary for the cyclotron-driven production of <strong><sup>67<\/sup>Cu<\/strong>, i.e., the development of a robust target manufacturing technology and recovery, as well as the related target processing system, aimed at attaining clinical grade batches of <strong><sup>67<\/sup>Cu<\/strong> useful for <em>in vivo<\/em>\/preclinical investigations coupled with new <strong>Cu<\/strong>-labeled prototype carriers.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"462\" src=\"https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13-1024x462.png\" alt=\"Main project goals\" class=\"wp-image-1444\" srcset=\"https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13-1024x462.png 1024w, https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13-1536x694.png 1536w, https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13-300x135.png 300w, https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13-768x347.png 768w, https:\/\/web.infn.it\/LARAMED\/wp-content\/uploads\/2023\/07\/image-13.png 2002w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">CUPRUM_TTD project goals.<\/figcaption><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<ul class=\"wp-block-list has-theme-palette-3-color has-text-color has-link-color has-small-font-size wp-elements-8f86b34f9eb8fcbd98d643ae960a2948\">\n<li><em>More information can be found here:<\/em><\/li>\n\n\n\n<li>Cisternino, S.;\u00a0Kotliarenko, A.; Martini, P.; Piteo, G.; Porto, F.;\u00a0Speltri, G.; Marvelli, L.;\u00a0Pigato, M.; Cazzola, E.; Boschi, A.; et al. Spark Plasma Sintering in Manufacturing and Recycling of\u00a0ZnO\u00a0Targets for Medical Radioisotopes Cyclotron-Based Production. Ceramics International\u00a0<strong>2025<\/strong>, doi:10.1016\/j.ceramint.2025.04.262.<\/li>\n\n\n\n<li>L. Mou, P. Martini, <strong>G. Pupillo<\/strong>, I. Cieszykowska, C.S. Cutler and R. Miko\u0142ajczak, <sup>67<\/sup>Cu production capabilities: a mini review 2022 Molecules DOI: 10.3390\/molecules27051501 <a href=\"https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1501\">https:\/\/www.mdpi.com\/1420-3049\/27\/5\/1501<\/a><\/li>\n\n\n\n<li>L. De Nardo, <strong>G. Pupillo<\/strong>, L. Mou, J. Esposito, A. Rosato and L. Mel\u00e9ndez-Alafort, A feasibility study of the Therapeutic Application of a Mixture of <sup>67\/64<\/sup>Cu Radionuclides produced by cyclotrons with proton irradiation, Medical Physics(2022) DOI: 10.1002\/mp.15524 <a href=\"https:\/\/aapm.onlinelibrary.wiley.com\/doi\/full\/10.1002\/mp.15524\">https:\/\/aapm.onlinelibrary.wiley.com\/doi\/full\/10.1002\/mp.15524<\/a><\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CUPRUM_TTD (INFN-CSN5, 2023-2025) CUPRUM_TTD project, acronym for &#8220;67\/64Cu PRoduction and Use in Medicine and Target Technology Development&#8221; is dedicated to the production of copper radionuclides 67\/64Cu, currently considered among the best-suited isotopes for radioimmunotherapy and theranostic applications, used as single isotopes, or in pair. Currently, the large-scale production of 67Cu still remains challenging: only a&#8230;<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_themeisle_gutenberg_block_has_review":false,"_kad_post_transparent":"","_kad_post_title":"hide","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-629","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/comments?post=629"}],"version-history":[{"count":8,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/629\/revisions"}],"predecessor-version":[{"id":3209,"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/pages\/629\/revisions\/3209"}],"wp:attachment":[{"href":"https:\/\/web.infn.it\/LARAMED\/wp-json\/wp\/v2\/media?parent=629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}